SCHEMBL1747899

SCHEMBL1747899

Nc1nc[nH]c2ccnc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 3/20 0.37
KDM4B O94953 3/20 0.37
KDM5B Q9UGL1 3/20 0.37
KDM5C P41229 2/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
GDA Q9Y2T3 2/20 0.36
MMP12 P39900 1/20 0.33
PI4KA P42356 2/20 0.32
PI4K2B Q8TCG2 2/20 0.32
PI4K2A Q9BTU6 2/20 0.32
PI4KB Q9UBF8 2/20 0.32
LMNA P02545 1/20 0.32
DRD3 P35462 1/20 0.32
XDH P47989 1/20 0.32
LRRK2 Q5S007 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
PNP P00491 1/20 0.32
PDPK1 O15530 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3353320 0.98 KDM4A (0.36) KDM4AKDM4BKDM5BKDM5CCDK5
Formic Acid SCHEMBL31745120 0.89 GDA (0.38) KDM4AKDM4BKDM5BKDM5CCDK5
SCHEMBL1056425 0.74 KDM4A (0.37) KDM4AKDM4BKDM5BKDM5CCDK5
SCHEMBL1374153 0.74 KDM4A (0.37) KDM4AKDM4BKDM5BKDM5CCDK5
SCHEMBL31485777 0.74 KDM4A (0.37) KDM4AKDM4BKDM5BKDM5CCDK5
SCHEMBL29696567 0.71 GDA (0.39) KDM4AKDM4BKDM5BKDM5CGDA
SCHEMBL60386 0.68 KDM4A (0.33) KDM4AKDM4BKDM5BKDM5CNOS3
SCHEMBL1800839 0.68 CDK5 (0.42) CDK5CDK5R1MMP12PI4KBKDM4E
SCHEMBL28369641 0.65 GDA (0.37) GDAPDPK1KDM4EMAPT
SCHEMBL4838539 0.65 MMP12 (0.39) CDK5CDK5R1MMP12NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865965-B Pyrrolopyrimidine-4-amine and pyrazolopyrimidine-4-amine derivatives, preparation method and application thereof 贵州省天然产物研究中心 2024-06-28 CN claimed
CN-117865965-A Pyrrolopyrimidine-4-amine and pyrazolopyrimidine-4-amine derivatives, preparation method and application thereof 贵州省天然产物研究中心 2024-04-12 CN claimed
CN-111454261-A Synthesis method of 4-chloro-pyrrolopyrimidine compound 南京普锐达医药科技有限公司 2020-07-28 CN claimed
CN-107803189-B Chromatography medium using 4-amino pyrrolo [3,2-D ] pyrimidine as functional ligand 苏州博进生物技术有限公司 2020-07-14 CN claimed
WO-1997049706-A1 SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF NOVARTIS AG (CH) 1997-12-31 WO claimed
CN-121758450-A Preparation method of pyrrolopyrimidine-4-amine derivative 山东轩硕医药科技有限公司 2026-03-31 CN disclosed
CN-121758450-A Preparation method of pyrrolopyrimidine-4-amine derivative 山东轩硕医药科技有限公司 2026-03-31 CN disclosed
US-20250382305-A1 COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC THERAPEUTICS INC (US) 2025-12-18 US disclosed
CN-119528862-A Dehydrocostuslactone derivative and preparation method and medical application thereof 昆明理工大学 2025-02-28 CN disclosed
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
CN-117865965-B Pyrrolopyrimidine-4-amine and pyrazolopyrimidine-4-amine derivatives, preparation method and application thereof 贵州省天然产物研究中心 2024-06-28 CN disclosed
CN-117865965-B Pyrrolopyrimidine-4-amine and pyrazolopyrimidine-4-amine derivatives, preparation method and application thereof 贵州省天然产物研究中心 2024-06-28 CN disclosed
US-6020492-A Deazapurine derivatives; a new class of CRF1 specific ligands NEUROGEN CORPORATION (US) 2000-02-01 US disclosed
US-5985848-A EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 1999-11-16 US disclosed
EP-0770080-B1 NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS NEUROGEN CORP (US) 1999-07-14 EP disclosed
EP-0674641-B1 PYRROLOPYRIMIDINES AS CRF ANTAGONISTS PFIZER (US) 1999-03-03 EP disclosed
US-5644057-A Deazapurine derivatives; a new class of CRF1 specific ligands NEUROGEN CORPORATION (US) 1997-07-01 US disclosed
EP-0729758-A2 Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders PFIZER INC. (US) 1996-09-04 EP disclosed
EP-0674641-A1 PYRROLOPYRIMIDINES AS CRF ANTAGONISTS PFIZER INC. (US) 1995-10-04 EP disclosed
WO-1994013676-A1 PYRROLOPYRIMIDINES AS CRF ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382305-A1 COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 ATXN2, SMN1; SMN2, ATXN10 KDM4A 3102/4885KDM4B 3076/4885KDM5B 3239/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL KDM4A 2568/4885KDM4B 2236/4885KDM5B 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.